Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.21037/tau.2017.12.07 http://scihub22266oqcxt.onion/10.21037/tau.2017.12.07 C6043742!6043742!30050793     free     free     free       Transl+Androl+Urol 2018 ; 7 (3): 321-9 Nephropedia Template TP {{tp|p=30050793|t=2018. Moderate hypofractionation for prostate cancer |pdf=|usr=}}{{30050793}} gab.com Text Moderate hypofractionation for prostate cancer JO: Transl Androl Urol http://www.kidney.de/pget.php?&tw=1&pmid=30050793 #FOAvip The biologic effects of changing the daily radiation dose (fractionation) have been studied for more than a century. The fractionation question in the treatment of prostate cancer came into stark relief in 1999 with the publication of a provocative report suggesting that hypofractionated regimens could maintain the therapeutic ratio with logistic and financial advantages. In the last two decades medical evidence, weak and strong, has accumulated on the efficacy and toxicity of hypofractionated regimens in the radiotherapeutic treatment of prostate cancer. This brief review will focus on the results of randomized trials that compare moderate hypofractionation (HF) to conventional fractionation (CF). Extreme HF is covered in a separate review within this issue. Twit Text FOAVip Moderate hypofractionation for prostate cancer ????Transl Androl Urol http://www.kidney.de/pget.php?&tw=1&pmid=30050793 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30050793 #FOAvip English Wikipedia <ref>{{Cite pmid|30050793}}</ref> Moderate hypofractionation for prostate cancer #MMPMID30050793 Lee WR; Koontz BF Transl Androl Urol 2018[Jun]; 7 (3): 321-9 PMID30050793show ga The biologic effects of changing the daily radiation dose (fractionation) have been studied for more than a century. The fractionation question in the treatment of prostate cancer came into stark relief in 1999 with the publication of a provocative report suggesting that hypofractionated regimens could maintain the therapeutic ratio with logistic and financial advantages. In the last two decades medical evidence, weak and strong, has accumulated on the efficacy and toxicity of hypofractionated regimens in the radiotherapeutic treatment of prostate cancer. This brief review will focus on the results of randomized trials that compare moderate hypofractionation (HF) to conventional fractionation (CF). Extreme HF is covered in a separate review within this issue. äModerate hypofractionation for prostate cancer (epmc).pdf DeepDyve Pubget Overpricing